Understanding Your Lipid Panel and Beyond
The standard lipid panel reports: Total Cholesterol, LDL-C (calculated or measured), HDL-C, and Triglycerides. LDL-C (LDL cholesterol) — the primary focus of cardiovascular risk assessment and statin therapy — represents the total cholesterol carried within LDL particles. The problem: LDL-C doesn’t directly measure cardiovascular risk from LDL because it doesn’t account for particle number or particle size. Two people with identical LDL-C of 130mg/dL may have dramatically different cardiovascular risk depending on whether they have 1,500 large, fluffy LDL particles or 2,200 small, dense LDL particles per deciliter.
ApoB (apolipoprotein B) is the protein that coats every LDL particle — exactly one ApoB per atherogenic particle. Since each LDL particle carries one ApoB molecule, ApoB directly measures LDL particle number, eliminating the particle size confounding. Multiple large prospective studies (AMORIS, INTERHEART, EPIC) show that ApoB is a superior predictor of cardiovascular events compared to LDL-C or LDL-particle number. Current cardiology guidelines are increasingly incorporating ApoB as a preferred risk marker — particularly for people with metabolic syndrome or type 2 diabetes, in whom the discordance between LDL-C and actual atherogenic particle burden is greatest. Optimal ApoB: below 80mg/dL for average-risk adults; below 65mg/dL for high-risk individuals.
HDL cholesterol (the “good cholesterol”) has a more complicated story than its reputation suggests. Population studies show lower HDL is associated with higher cardiovascular risk, establishing it as an inverse risk marker. However, multiple large trials attempting to raise HDL pharmacologically (niacin in AIM-HIGH and HPS2-THRIVE trials; CETP inhibitors in ILLUMINATE and dal-OUTCOMES) failed to reduce cardiovascular events despite substantially raising HDL-C — raising doubts about HDL-C as a causal protective factor. The current understanding: HDL function (particularly its capacity to accept cholesterol from arterial walls and transport it to the liver — “reverse cholesterol transport capacity”) rather than HDL-C level per se is the important variable. Dysfunctional HDL — which can actually be pro-inflammatory — is found in metabolic syndrome, diabetes, and smoking.
Triglycerides — fats transported in VLDL particles — reflect short-term dietary fat intake but more importantly reflect carbohydrate metabolism. Elevated triglycerides (above 150mg/dL) are a primary marker of insulin resistance and carbohydrate overconsumption, particularly fructose. High triglycerides occur alongside low HDL as part of the atherogenic dyslipidemia characteristic of metabolic syndrome — a combination (high TG + low HDL + small dense LDL) that dramatically elevates cardiovascular risk even when LDL-C appears normal. Optimal triglycerides are below 100mg/dL; levels of 500mg/dL+ require urgent treatment due to pancreatitis risk.